文献速递前列腺癌

基质基因表达可预测转移性原发性前列腺癌

Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
PubMed 文献 · Eur Urol · 2017-03-19

基于5个来自同一原发肿瘤不同病灶、具不同转移表型的前列腺癌患者来源异种移植模型的全基因组和全转录组测序,构建了93基因基质来源转移特征(SDMS),并在多个独立临床队列(含中危队列)中验证;SDMS评分较高患者预后较差,SDMS为独立预后因素,可对中危前列腺癌进行风险分层并改善其他已报道特征的性能。

要点

  • SDMS为基于基质基因表达的93基因转移特征,在多个独立临床队列中验证。
  • SDMS评分较高患者预后较差,且为独立预后因素。
  • SDMS可对中危前列腺癌进行风险分层并改善其他已报道特征的性能。

核心结论

  • 基质基因表达谱分析构建的SDMS被验证为前列腺肿瘤转移潜能的独立预后因素。

研究设计与样本

  • 对5个来自单一原发肿瘤独立病灶、具不同转移表型的前列腺癌患者来源异种移植模型进行全基因组和全转录组测序以开发特征。
  • 使用多个独立临床队列(包括一个中危队列)验证生物标志物。
  • 采用带lasso正则化的广义线性模型构建93基因基质来源转移特征(SDMS)。

主要发现

  • 观察到基质基因表达与转移表型密切关联。
  • SDMS评分较高患者预后较差。
  • SDMS为独立预后因素,可对中危前列腺癌进行风险分层。
  • SDMS可改善其他已报道特征的性能。

关键数值与推荐

  • SDMS与转移的关联使用Wilcoxon秩和检验评估。
  • 性能使用受试者工作特征曲线下面积(AUC)和Kaplan-Meier曲线评估。
  • 使用单变量和多变量回归模型将SDMS与临床病理变量及已报道特征进行比较。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical grading systems using clinical features alongside nomograms lack precision in guiding treatment decisions in prostate cancer (PCa). There is a critical need for identification of biomarkers that can more accurately stratify patients with primary PCa. OBJECTIVE: To identify a robust prognostic signature to better distinguish indolent from aggressive prostate cancer (PCa). DESIGN, SETTING, AND PARTICIPANTS: To develop the signature, whole-genome and whole-transcriptome sequencing was conducted on five PCa patient-derived xenograft (PDX) models collected from independent foci of a single primary tumor and exhibiting variable metastatic phenotypes. Multiple independent clinical cohorts including an intermediate-risk cohort were used to validate the biomarkers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome measurement defining aggressive PCa was metastasis following radical prostatectomy. A generalized linear model with lasso regularization was used to build a 93-gene stroma-derived metastasis signature (SDMS). The SDMS association with metastasis was assessed using a Wilcoxon rank-sum test. Performance was evaluated using the area under the curve (AUC) for the receiver operating characteristic, and Kaplan-Meier curves. Univariable and multivariable regression models were used to compare the SDMS alongside clinicopathological variables and reported signatures. AUC was assessed to determine if SDMS is additive or synergistic to previously reported signatures. RESULTS AND LIMITATIONS: A close association between stromal gene expression and metastatic phenotype was observed. Accordingly, the SDMS was modeled and validated in multiple independent clinical cohorts. Patients with higher SDMS scores were found to have worse prognosis. Furthermore, SDMS was an independent prognostic factor, can stratify risk in intermediate-risk PCa, and can improve the performance of other previously reported signatures. CONCLUSIONS: Profiling of stromal gene expression led to development of an SDMS that was validated as independently prognostic for the metastatic potential of prostate tumors. PATIENT SUMMARY: Our stroma-derived metastasis signature can predict the metastatic potential of early stage disease and will strengthen decisions regarding selection of active surveillance versus surgery and/or radiation therapy for prostate cancer patients. Furthermore, profiling of stroma cells should be more consistent than profiling of diverse cellular populations of heterogeneous tumors.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Mo F, Lin D, Takhar M, et al. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. Eur Urol. 2017. PMID: 28330676. doi:10.1016/j.eururo.2017.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。